Healthcare Industry News: Alzheimer's
News Release - March 22, 2007
Sanarus Medical, Inc. Appoints John F. Howe as President and Chief Executive OfficerPLEASANTON, Calif., March 22 (HSMN NewsFeed) -- Sanarus Medical, Inc., a leading developer of minimally invasive medical devices for diagnosing and treating breast disease, announced today that John F. Howe has been promoted to the position of President and Chief Executive Officer. Mr. Howe has been the Chief Operating and Chief Financial Officer for the company since November 2005. He replaces John Rush, who resigned his position with Sanarus as President and CEO. Effective mid-April, Mr. Rush will be taking on a new role as President and CEO of North American Scientific. "The entire Sanarus family would like to thank John Rush for his outstanding leadership over the last four years," stated John Howe. "Sanarus is positioned to become the leader in the breast care industry and John Rush was instrumental in this effort."
Mr. Howe, 54, has more than 26 years of senior management experience in the medical device industry. Prior to joining Sanarus, Mr. Howe had been the Chief Financial Officer for Eunoe, Inc. a venture backed medical device company that focused on the development and clinical testing of a treatment for Alzheimer's disease. From 1999 to 2002, Mr. Howe held the position of Chief Financial Officer for VidaMed, Inc., a publicly traded medical device company specializing in RF energy based urological systems for treating enlarged prostates that was sold to Medtronic in 2002. In addition Mr. Howe has held several senior level financial and operational positions with Nellcor Puritan Bennett, and with IVAC Corporation, a subsidiary of Eli Lilly.
"We would like to thank John Rush for his contributions and wish him the best in his new endeavors," stated Farah Champsi, Managing Director of Alta Partners and Director of Sanarus. "We are delighted to promote John Howe to President and CEO. Mr. Howe is an executive with outstanding qualifications and an intimate knowledge of the Company's operations. We look forward to his leadership of Sanarus as it continues its momentum in commercializing products for minimally invasive breast surgery."
About Sanarus Medical
Sanarus Medical, Inc., headquartered in Pleasanton, California, is dedicated to advancing women's health by providing a full line of minimally invasive products for the diagnosis and treatment of breast disease. The company is founded in innovative proprietary cryo-technologies uniquely designed for breast biopsy, tumor localization and ablation. The Sanarus cryoablation technology enables a safe and effective office-based procedure at reduced cost. This provides an important alternative for women that currently have to undergo an operating room based, surgically intensive procedure. Privately held, Sanarus Medical is funded by leading healthcare venture capital investors, including U.S. Venture Partners, Forward Ventures, Federated Kaufman Funds, Alta Partners, Pequot Ventures, Easton Capital Partners, Mosaix Ventures, Industry Ventures, and CHANNEL Medical Partners. For more information, visit our website at www.sanarus.com.
Source: Sanarus Medical
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.